Detail akcie Vera Therapeut Rg-A online

Business Summary: Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. It is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. It retains all global developmental and commercial rights to atacicept and MAU868.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Vera Therapeutics Inc revenues was not reported. Net loss increased 92% to $208.5M. Higher net loss reflects Biotechnology segment loss increase of 87% to $221.3M, United States segment loss increase of 87% to $221.3M. Basic Earnings per Share excluding Extraordinary Items decreased from -$2.02 to -$3.27.